These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 6489413

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S, Orö L.
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [Abstract] [Full Text] [Related]

  • 4. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P, Bittolo Bon G, Belussi F, Pontoglio E, Cazzolato G.
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR.
    Artery; 1985 Apr; 12(6):363-81. PubMed ID: 4051756
    [Abstract] [Full Text] [Related]

  • 11. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
    Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Grundy SM, Knopp RH, Lasser NL, Mellies MJ, Palmer RH, Samuel P.
    Arteriosclerosis; 1986 Apr; 6(6):670-8. PubMed ID: 3535757
    [Abstract] [Full Text] [Related]

  • 12. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR, Callaghan DJ, Theiss U.
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [Abstract] [Full Text] [Related]

  • 19. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D, Oschry Y, Fainaru M, Eisenberg S.
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.